Physiomics PLC Contract award and update (5736R)
30 Junio 2020 - 8:30AM
UK Regulatory
TIDMPYC
RNS Number : 5736R
Physiomics PLC
30 June 2020
30 June 2020
Physiomics plc
("Physiomics") or (the "Company")
Contract award and update
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models and its Virtual Tumour(TM) technology to
support the development of cancer treatment regimens and
personalised medicine solutions, is pleased to announce that it has
been awarded a further contract of undisclosed value by existing
client Bicycle Therapeutics plc (Nasdaq: BCYC) ("Bicycle"). The
project involves advanced translational pharmacokinetic modelling
of one of Bicycle's pipeline assets and represents the fourth
Bicycle asset for which the Company has provided modelling support.
The project is likely to last around two months.
In addition, the Company would like to confirm that it is in the
late stages of agreeing a contract with the potential new large
pharmaceutical client that was originally referred to in its
placing announcement of 27 May 2020. As noted in that announcement,
the project would take two of our technical staff around five
months to complete. The Company will provide a further update on
this in due course, as and when appropriate.
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulations (EU) No. 596/2014.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0)20 3764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC ) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 70 projects, involving over 30 targets and
60 drugs, and has worked with clients such as Merck KGaA, Merck
& Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDEADKEDAKEEFA
(END) Dow Jones Newswires
June 30, 2020 09:30 ET (13:30 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De May 2023 a May 2024